WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004009769) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/009769    International Application No.:    PCT/US2003/022444
Publication Date: 29.01.2004 International Filing Date: 18.07.2003
Chapter 2 Demand Filed:    24.02.2004    
IPC:
A61K 38/00 (2006.01), C12N 15/11 (2006.01)
Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Suite 200, 3160 Chestnut Street, Philadelphia, PA 19104-6283 (US) (For All Designated States Except US).
TOLENTINO, Michael, J.. [US/US]; (US) (For US Only).
REICH, Samuel, Jotham [US/US]; (US) (For US Only)
Inventors: TOLENTINO, Michael, J..; (US).
REICH, Samuel, Jotham; (US)
Agent: FRANK, George, A.; Drinker Biddle & Reath LLP, One Logan Square, 18th and Cherry Streets, Philadelphia, PA 19103-6996 (US)
Priority Data:
60/398,417 24.07.2002 US
10/294,228 14.11.2002 US
Title (EN) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
(FR) COMPOSITIONS ET PROCEDE D'INHIBITION DE L'ANGIOGENESE PAR ARN-SI
Abstract: front page image
(EN)RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt­1 and Flk-l/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
(FR)L'invention concerne l'interférence d'ARN utilisant de petits ARN d'interférence qui sont spécifiques au gène du facteur de croissance vasculaire endothélial (VEGF) et aux gènes récepteurs de VEGF Flt-1 et Flk-l/KDR, qui inhibent l'expression de ces gènes. On peut traiter des maladies liées à l'angiogenèse stimulée par la surexpression de VEGF telles que la rétinopathie diabétique, la dégénérescence musculaire liée au vieillissement et de nombreux types de cancer, et ce grâce à l'administration de petits ARN d'interférence.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)